Adagene Stock News

Adagene Inc. (NASDAQ:ADAG) Stock analysts at Jefferies Financial Group reduced their FY2025 earnings per share (EPS) estimates for shares of Adagene in a report issued on Tuesday, December 7th. Jefferies Financial Group analyst K. Shi now forecasts that the company will post earnings per share of ($5.50) for the year, down from their prior []

Adagene (NASDAQ:ADAG) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Earnings and Valuation This table compares Adagene and MacroGenics gross revenue, earnings per share and valuation. Gross [] The post Adagene (NASDAQ:ADAG) & MacroGenics (NASDAQ:MGNX) Critical Review appeared first on ETF Daily News .

Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab

- Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab - - Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab -

Adagene (NASDAQ:ADAG) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Profitability This table compares Adagene and MacroGenics net margins, return on equity and return on assets. Net []

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

The FDA has cleared Adagene Inc''s (NASDAQ: ADAG ) Investigational New Drug (IND) application to proceed with a Phase 1b/2 trial of ADG116, in combination with Merck & Co Inc (NYSE: MRK ) Keytruda (pembrolizumab). The global trial (ADG116-P001 / KEYNOTE-C97) will evaluate patients with advanced/metastatic solid tumors at multiple sites in Full story available on Benzinga.com

The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Investigational New Drug (IND) application to proceed with a Phase 1b/2 trial of ADG116, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (

The stock price of Adagene Inc (NASDAQ: ADAG) increased by over 15% pre-market today. This is why it happened.

ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022 ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022

SAN DIEGO and SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (Adagene) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced two poster presentations featuring clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116, at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021.

Adagene Inc. (NASDAQ:ADAG) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 148,500 shares, a drop of 27.5% from the October 14th total of 204,700 shares. Based on an average trading volume of 20,200 shares, the days-to-cover ratio is presently 7.4 days. Approximately []

Related Stocks: LYEL , RLX , ILMN , ADAG , EDR , EDR , DOYU ,

SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transf

- Established three clinical collaborations with Merck to conduct global combination trials  with pembrolizumab for three clinical-stage oncology candidates -